{"id":64440,"date":"2022-03-09T06:47:00","date_gmt":"2022-03-08T23:47:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2022030906470064440"},"modified":"2022-03-09T18:14:47","modified_gmt":"2022-03-09T10:14:47","slug":"%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82022%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%ef%bc%88aacr%ef%bc%89%e5%b9%b4%e4%bc%9a","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2022030906470064440","title":{"rendered":"\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282022\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\u516d\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022022\u5e743\u67089\u65e5 \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a — \u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u5171\u6709\u4e94\u4e2a\u5728\u7814\u4ea7\u54c1\u7684\u516d\u9879\u4e34\u5e8a\u524d\u8fdb\u5c55\u5165\u90092022\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\uff0c\u5305\u62ec\u7ec6\u80de\u51cb\u4ea1\u7ba1\u7ebf\u91cd\u8981\u54c1\u79cdBcl-2\u6291\u5236\u5242lisaftoclax\uff08APG-2575\uff09\u3001MDM2-p53 \u6291\u5236\u5242alrizomadlin\uff08APG-115\uff09\uff0cFAK\u6291\u5236\u5242APG-2449\uff0cEED\u6291\u5236\u5242APG-5918\u7b49\u3002\u6458\u8981\u5185\u5bb9\u73b0\u5df2\u5728AACR\u5b98\u7f51\u516c\u5e03\u3002<\/p>\n

\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u662f\u5168\u7403\u5386\u53f2\u6700\u60a0\u4e45\u3001\u89c4\u6a21\u6700\u5927\u7684\u80bf\u7624\u7814\u7a76\u5b66\u672f\u4f1a\u8bae\u4e4b\u4e00\u3002\u4f1a\u8bae\u5173\u6ce8\u9ad8\u8d28\u91cf\u80bf\u7624\u7814\u7a76\u53ca\u521b\u65b0\u7684\u5404\u4e2a\u65b9\u9762\uff0c\u662f\u5168\u7403\u80bf\u7624\u7814\u7a76\u7684\u7126\u70b9\uff0c\u5c06\u6c47\u96c6\u80bf\u7624\u9886\u57df\u7684\u6700\u524d\u6cbf\u7684\u7814\u7a76\u6210\u679c\u3002\u672c\u5c4aAACR\u5e74\u4f1a\u5c06\u4e8e\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f42022\u5e744\u67088\u65e5-13\u65e5\u5728\u7f8e\u56fd\u65b0\u5965\u5c14\u826f\u4e3e\u884c\u3002<\/p>\n

\u4e9a\u76db\u533b\u836f\u7684\u516d\u9879\u7814\u7a76\u8fdb\u5c55\u6458\u8981\u5982\u4e0b\uff1a<\/p>\n

\u4ea7\u54c1\uff1aAPG-2575\u548cAPG-115<\/u><\/b><\/p>\n

Co-targeting MDM2-p53 and BCL-2 apoptosis pathways overcomes resistance conferred by acquired BCL-2 gene mutations in preclinical models
<\/b>\u53cc\u91cd\u9776\u5411MDM2-p53\u548cBCL-2\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u53ef\u514b\u670d\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u83b7\u5f97\u6027BCL-2\u57fa\u56e0\u7a81\u53d8\u5bfc\u81f4\u7684\u8010\u836f<\/b><\/p>\n

    \n
  • \u6458\u8981\u7f16\u53f7\uff1a3964 <\/li>\n
  • \u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics\uff08\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\uff09 <\/li>\n
  • \u5206\u4f1a\u573a\u6807\u9898\uff1aHematological and Pediatric Malignancy and Sarcoma Treatment Resistance\uff08\u8840\u6db2\u548c\u513f\u79d1\u6076\u6027\u80bf\u7624\u548c\u8089\u7624\u7684\u8010\u836f\u6027\uff09 <\/li>\n
  • \u5206\u4f1a\u573a\u65f6\u95f4\uff1a2022\u5e744\u670813\u65e5 9:00 AM – 12:30 PM<\/span><\/li>\n<\/ul>\n

    BCL-2\u57fa\u56e0\u7a81\u53d8\u662f\u4e34\u5e8a\u4e0aBCL-2\u6291\u5236\u5242\u8010\u836f\u7684\u91cd\u8981\u673a\u5236\uff0c\u800c\u8be5\u7814\u7a76\u53d1\u73b0\u53cc\u91cd\u9776\u5411<\/b>MDM2-p53\u548cBCL-2\u7ec6\u80de\u51cb\u4ea1\u901a\u8def<\/b>\u514b\u670d\u4e86\u6b64\u8010\u836f\u6027\uff0c\u4ece\u800c\u4e3a\u4e34\u5e8a\u8bd5\u9a8c\u63d0\u4f9b\u4e86\u5f88\u597d\u7684\u7814\u7a76\u4f9d\u636e\uff0c\u4e3a\u514b\u670dBCL-2\u6291\u5236\u5242\u4e34\u5e8a\u8010\u836f\u63d0\u4f9b\u4e86\u53ef\u884c\u7684\u7b56\u7565\u3002<\/p>\n

    \u4ea7\u54c1\uff1aAPG-115<\/u><\/b><\/p>\n

    Inhibition of MDM2-p53 interaction by alrizomadlin (APG-115) induces pyroptotic cell death in gasdermin E (GSDME)-expressing cancer cells
    <\/b>Alrizomadlin (APG-115) \u5bf9\u4e8eMDM2-p53\u76f8\u4e92\u4f5c\u7528\u7684\u6291\u5236\u53ef\u8bf1\u5bfcgasdermin E (GSDME) \u9633\u6027\u764c\u7ec6\u80de\u7684\u7126\u4ea1\u6027\u7ec6\u80de\u6b7b\u4ea1<\/b><\/p>\n

      \n
    • \u6458\u8981\u7f16\u53f7\uff1a2998 <\/li>\n
    • \u5206\u4f1a\u573a\u7c7b\u522b\uff1aMolecular\/Cellular Biology and Genetics\uff08\u5206\u5b50\/\u7ec6\u80de\u751f\u7269\u5b66\u548c\u9057\u4f20\u5b66\uff09 <\/li>\n
    • \u5206\u4f1a\u573a\u6807\u9898\uff1aNon-apoptotic Cell Death \/ Autophagy\uff08\u975e\u51cb\u4ea1\u6027\u7ec6\u80de\u6b7b\u4ea1\/\u81ea\u566c\uff09 <\/li>\n
    • \u5206\u4f1a\u573a\u65f6\u95f4\uff1a2022\u5e744\u670812\u65e5 1:30 PM – 5:00 PM<\/span><\/li>\n<\/ul>\n

      \u8be5\u7814\u7a76\u7ed3\u679c\u53d1\u73b0MDM2-p53\u6291\u5236\u5242APG-115\u9664\u8bf1\u5bfc\u7ec6\u80de\u51cb\u4ea1\u5916\u7684\u4e00\u79cd\u65b0\u4f5c\u7528\u673a\u7406\u3002\u5728\u8868\u8fbeGSDME\u7684\u80bf\u7624\u7ec6\u80de\u4e2d\uff0cAPG-115\u53ef\u8bf1\u5bfc\u7ec6\u80de\u7126\u4ea1\uff0c\u91ca\u653e\u708e\u6027\u7ec6\u80de\u56e0\u5b50\u3002<\/p>\n

      MDM2 inhibitor alrizomadlin (APG-115) stabilizes p53 and synergizes with proteasome inhibitors in multiple myeloma
      <\/b>MDM2\u6291\u5236\u5242alrizomadlin (APG-115)\u53ef\u7a33\u5b9a\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u4e2d\u7684p53\u5e76\u4e0e\u86cb\u767d\u9176\u4f53\u6291\u5236\u5242\u5177\u6709\u534f\u540c\u4f5c\u7528<\/b><\/p>\n

        \n
      • \u6458\u8981\u7f16\u53f7\uff1a5439 <\/li>\n
      • \u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics\uff08\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\uff09 <\/li>\n
      • \u5206\u4f1a\u573a\u6807\u9898\uff1aSmall Molecule Therapeutic Agents (\u5c0f\u5206\u5b50\u6cbb\u7597\u836f\u7269) <\/li>\n
      • \u5206\u4f1a\u573a\u65f6\u95f4\uff1a2022\u5e744\u67088\u65e5 12:00 PM<\/span> \u2013 1:00 PM<\/span><\/li>\n<\/ul>\n

        \u8be5\u7814\u7a76\u7ed3\u679c\u8868\u660e\uff0cMDM2-p53\u6291\u5236\u5242APG-115\u548c\u86cb\u767d\u9176\u4f53\u6291\u5236\u5242\u8054\u7528\u5bf9TP53\u91ce\u751f\u578b\u7684\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u5177\u6709\u534f\u540c\u6297\u80bf\u7624\u4f5c\u7528\u3002<\/p>\n

        \u4ea7\u54c1\uff1aAPG-2449<\/u><\/b><\/p>\n

        FAK inhibitor APG-2449 and CDK4\/6 inhibitor palbociclib synergistically suppress mesothelioma tumor growth via autophagy induction
        <\/b>FAK\u6291\u5236\u5242APG-2449\u4e0eCDK4\/6\u6291\u5236\u5242palbociclib\u901a\u8fc7\u8bf1\u5bfc\u81ea\u566c\u8fbe\u5230\u5bf9\u95f4\u76ae\u7624\u751f\u957f\u7684\u534f\u540c\u6291\u5236<\/b><\/p>\n

          \n
        • \u6458\u8981\u7f16\u53f7\uff1a2563 <\/li>\n
        • \u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics\uff08\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\uff09 <\/li>\n
        • \u5206\u4f1a\u573a\u6807\u9898\uff1aCell Cycle, Replication Inhibitors, and Immunotherapy Agents\uff08\u7ec6\u80de\u5468\u671f\u3001\u589e\u6b96\u6291\u5236<\/span>\u5242\u548c\u514d\u75ab\u6cbb\u7597\u836f\u7269\uff09 <\/li>\n
        • \u5206\u4f1a\u573a\u65f6\u95f4\uff1a2022\u5e744\u670812\u65e5 9:00 AM – 12:30 PM<\/span><\/li>\n<\/ul>\n

          \u8be5\u7814\u7a76\u7ed3\u679c\u8868\u660e\uff0c\u5728\u95f4\u76ae\u7624\u76f8\u5173\u7684\u6a21\u578b\u4e2d\uff0cFAK\u6291\u5236\u5242APG-2449\u53ef\u901a\u8fc7\u8bf1\u53d1\u80bf\u7624\u7ec6\u80de\u7684\u81ea\u566c\u7684\u53d1\u751f\uff0c\u4ece\u800c\u8fbe\u5230\u6291\u5236\u80bf\u7624\u751f\u957f\uff0c\u5c55\u73b0\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u4e5f\u4e3a\u76f8\u5173\u4e34\u5e8a\u5b9e\u9a8c\u7684\u8bbe\u8ba1\u63d0\u4f9b\u7406\u8bba\u53c2\u8003\u3002<\/p>\n

          \u4ea7\u54c1\uff1aAPG-5918<\/u><\/b><\/p>\n

          Preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918\/EEDi-5273 for cancer therapy
          <\/b>\u6297\u80bf\u7624\u836f\u7269EED\u6291\u5236\u5242APG-5918\/EEDi-5273\u7684\u4e34\u5e8a\u524d\u7814\u7a76<\/b><\/p>\n

            \n
          • \u6458\u8981\u7f16\u53f7\uff1a3939 <\/li>\n
          • \u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics\uff08\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\uff09 <\/li>\n
          • \u5206\u4f1a\u573a\u6807\u9898\uff1aEmerging New Anticancer Agents\uff08\u65b0\u578b\u6297\u80bf\u7624\u836f\u7269\uff09 <\/li>\n
          • \u65f6\u95f4\uff1a2022\u5e744\u670813\u65e5 9:00 AM – 12:30 PM<\/span><\/li>\n<\/ul>\n

            \u8be5\u7814\u7a76\u7ed3\u679c\u8868\u660e\uff0cAPG-5918\u4f5c\u4e3a\u4e00\u4e2a\u5f3a\u6548\u7684EED\u6291\u5236\u5242\uff0c\u7279\u5f02\u6027\u5730\u6291\u5236\u80bf\u7624\u7ec6\u80de\u4e2d\u7684H3K27me3\u6c34\u5e73\uff0c\u5e76\u5728EZH2\u7a81\u53d8\u6216SMARCB1\u7f3a\u5931\u7684\u7ec6\u80de\u548c\u5c0f\u9f20\u80bf\u7624\u6a21\u578b\u4e2d\u663e\u793a\u51fa\u9ad8\u6548\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002<\/p>\n

            \u4ea7\u54c1\uff1aAPG-1842<\/u><\/b><\/p>\n

            Development of covalent KRASG12C<\/sup> inhibitor APG-1842 for the treatment of solid tumors
            <\/b>KRASG12C<\/sup>\u5171\u4ef7\u6291\u5236\u5242APG-1842\u7528\u4e8e\u6cbb\u7597\u5b9e\u4f53\u7624\u7684\u4e34\u5e8a\u524d\u5f00\u53d1<\/b><\/p>\n

              \n
            • \u6458\u8981\u7f16\u53f7\uff1a2664 <\/li>\n
            • \u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics\uff08\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\uff09 <\/li>\n
            • \u5206\u4f1a\u573a\u6807\u9898\uff1aSignaling Pathway Inhibitors\uff08\u4fe1\u53f7\u901a\u8def\u6291\u5236\u5242\uff09 <\/li>\n
            • \u65f6\u95f4\uff1a2022\u5e744\u670812\u65e5 9:00 AM – 12:30 PM<\/span><\/li>\n<\/ul>\n

              \u8be5\u7814\u7a76\u7ed3\u679c\u8868\u660e\uff0cAPG-1842\u4f5c\u4e3a\u4e00\u4e2a\u5168\u65b0\u7684KRASG12C<\/sup>\u9009\u62e9\u6027\u5171\u4ef7\u6291\u5236\u5242\uff0c\u7279\u5f02\u6027\u5730\u9776\u5411\u5904\u4e8e\u975e\u6d3b\u6027\u72b6\u6001\uff08GDP\u7ed3\u5408\uff09\u7684KRASG12C<\/sup>\u86cb\u767d\u4ece\u800c\u963b\u65adKRAS\u4fe1\u53f7\u4f20\u5bfc\u901a\u8def\uff0c\u5e76\u5728KRASG12C<\/sup>\u7a81\u53d8\u7684\u7ec6\u80de\u548c\u5c0f\u9f20\u80bf\u7624\u6a21\u578b\u4e2d\u663e\u793a\u51fa\u9ad8\u6548\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002<\/p>\n

              \u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/u><\/b><\/p>\n

              \u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n

              \u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u6700\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67098\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216 MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5550\u591a\u9879I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u7528\u4e8e\u6cbb\u7597\u8010\u836f\u6027\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cd\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u66fe\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u548c\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\uff0c\u5e76\u5df2\u5728\u4e2d\u56fd\u83b7\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u4e2a\u4e0a\u5e02\u54c1\u79cd\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u3001\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3001\u4ee5\u53ca\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9713\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002\u516c\u53f8\u5148\u540e\u627f\u62c5\u591a\u9879\u56fd\u5bb6\u79d1\u6280\u91cd\u5927\u4e13\u9879\uff0c\u5176\u4e2d\u201c\u91cd\u5927\u65b0\u836f\u521b\u5236\u201d\u4e13\u98795\u9879\uff0c\u5305\u62ec1\u9879\u201c\u4f01\u4e1a\u521b\u65b0\u836f\u7269\u5b75\u5316\u57fa\u5730\u201d\u53ca4\u9879\u201c\u521b\u65b0\u836f\u7269\u7814\u53d1\u201d\uff0c\u53e6\u5916\u627f\u62c5\u201c\u91cd\u5927\u4f20\u67d3\u75c5\u9632\u6cbb\u201d\u4e13\u98791\u9879\u3002<\/p>\n

              \u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0eUNITY\u3001MD Anderson\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u7b49\u9886\u5148\u7684\u751f\u7269\u6280\u672f\u53ca\u533b\u836f\u516c\u53f8\u3001\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u4e30\u5bcc\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u7ecf\u9a8c\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u540c\u65f6\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6807\u51c6\u6253\u9020\u540e\u671f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u53ca\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c\u201c\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u201d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n

              \u524d\u77bb\u6027\u58f0\u660e<\/u><\/b><\/p>\n

              \u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n

              \n<\/p><\/div>\n

               <\/p>\n

              <\/div>\n","protected":false},"excerpt":{"rendered":"

              \u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022022\u5e743\u67089\u65e5 \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a — \u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u5171\u6709\u4e94\u4e2a\u5728\u7814\u4ea7\u54c1\u7684\u516d\u9879\u4e34\u5e8a\u524d\u8fdb\u5c55\u5165\u90092022\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\uff0c\u5305\u62ec\u7ec6\u80de\u51cb\u4ea1\u7ba1\u7ebf\u91cd\u8981\u54c1\u79cdBcl-2\u6291\u5236\u5242lisaftoclax\uff08APG-2575\uff09\u3001MDM2-p53 \u6291\u5236\u5242alrizomadlin\uff08APG-115\uff09\uff0cFAK\u6291\u5236\u5242APG-2449\uff0cEED\u6291\u5236\u5242APG-5918\u7b49\u3002\u6458\u8981\u5185\u5bb9\u73b0\u5df2\u5728AACR\u5b98\u7f51\u516c\u5e03\u3002 \u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u662f\u5168\u7403\u5386\u53f2\u6700\u60a0\u4e45\u3001\u89c4\u6a21\u6700\u5927\u7684\u80bf\u7624\u7814\u7a76\u5b66\u672f\u4f1a\u8bae\u4e4b\u4e00\u3002\u4f1a\u8bae\u5173\u6ce8\u9ad8\u8d28\u91cf\u80bf\u7624\u7814\u7a76\u53ca\u521b\u65b0\u7684\u5404\u4e2a\u65b9\u9762\uff0c\u662f\u5168\u7403\u80bf\u7624\u7814\u7a76\u7684\u7126\u70b9\uff0c\u5c06\u6c47\u96c6\u80bf\u7624\u9886\u57df\u7684\u6700\u524d\u6cbf\u7684\u7814\u7a76\u6210\u679c\u3002\u672c\u5c4aAACR\u5e74\u4f1a\u5c06\u4e8e\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f42022\u5e744\u67088\u65e5-13\u65e5\u5728\u7f8e\u56fd\u65b0\u5965\u5c14\u826f\u4e3e\u884c\u3002 \u4e9a\u76db\u533b\u836f\u7684\u516d\u9879\u7814\u7a76\u8fdb\u5c55\u6458\u8981\u5982\u4e0b\uff1a \u4ea7\u54c1\uff1aAPG-2575\u548cAPG-115 Co-targeting MDM2-p53 and BCL-2 apoptosis pathways overcomes resistance conferred by acquired BCL-2 gene mutations in preclinical models\u53cc\u91cd\u9776\u5411MDM2-p53\u548cBCL-2\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u53ef\u514b\u670d\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u83b7\u5f97\u6027BCL-2\u57fa\u56e0\u7a81\u53d8\u5bfc\u81f4\u7684\u8010\u836f \u6458\u8981\u7f16\u53f7\uff1a3964 \u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics\uff08\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\uff09 \u5206\u4f1a\u573a\u6807\u9898\uff1aHematological and Pediatric Malignancy and Sarcoma Treatment Resistance\uff08\u8840\u6db2\u548c\u513f\u79d1\u6076\u6027\u80bf\u7624\u548c\u8089\u7624\u7684\u8010\u836f\u6027\uff09 \u5206\u4f1a\u573a\u65f6\u95f4\uff1a2022\u5e744\u670813\u65e5 9:00 AM – 12:30 PM BCL-2\u57fa\u56e0\u7a81\u53d8\u662f\u4e34\u5e8a\u4e0aBCL-2\u6291\u5236\u5242\u8010\u836f\u7684\u91cd\u8981\u673a\u5236\uff0c\u800c\u8be5\u7814\u7a76\u53d1\u73b0\u53cc\u91cd\u9776\u5411MDM2-p53\u548cBCL-2\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u514b\u670d\u4e86\u6b64\u8010\u836f\u6027\uff0c\u4ece\u800c\u4e3a\u4e34\u5e8a\u8bd5\u9a8c\u63d0\u4f9b\u4e86\u5f88\u597d\u7684\u7814\u7a76\u4f9d\u636e\uff0c\u4e3a\u514b\u670dBCL-2\u6291\u5236\u5242\u4e34\u5e8a\u8010\u836f\u63d0\u4f9b\u4e86\u53ef\u884c\u7684\u7b56\u7565\u3002 \u4ea7\u54c1\uff1aAPG-115 Inhibition of MDM2-p53 interaction by alrizomadlin (APG-115)… Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":64443,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-64440","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/64440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=64440"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/64440\/revisions"}],"predecessor-version":[{"id":64442,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/64440\/revisions\/64442"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/64443"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=64440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=64440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=64440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}